Repare Therapeutics (NASDAQ:RPTX) Announces Quarterly Earnings Results

Repare Therapeutics (NASDAQ:RPTX) released its quarterly earnings data on Monday. The company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.10, Zacks reports. Repare Therapeutics had a negative net margin of 99.76% and a negative return on equity of 40.87%.

Repare Therapeutics Stock Performance

RPTX stock traded up $0.03 during midday trading on Wednesday, reaching $1.20. 12,457 shares of the company traded hands, compared to its average volume of 293,934. The firm has a market capitalization of $50.80 million, a price-to-earnings ratio of -0.60 and a beta of 0.87. The business has a 50 day moving average of $1.26 and a 200-day moving average of $2.45. Repare Therapeutics has a 52-week low of $1.06 and a 52-week high of $6.73.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on RPTX shares. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Repare Therapeutics in a research note on Friday, November 8th. Bloom Burton cut Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, January 10th. Lifesci Capital reissued a “market perform” rating on shares of Repare Therapeutics in a report on Friday, December 13th. Finally, Stifel Nicolaus decreased their price target on shares of Repare Therapeutics from $9.00 to $4.00 and set a “buy” rating on the stock in a research note on Friday, December 13th.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.